Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 ELI LILLY (I4V-MC-JADY) Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 ELI LILLY (I1F-MC-RHBX) A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 ELI LILLY (I1F-MC-RHBY) A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 NOVARTIS (CQAW039A2317) A 12-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 AURINIA (AUR-VCS_2016-01) A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 NOVARTIS (CQAW039A2315) A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 ENANTA PHARMACEUTICALS, INC. (EDP-305) A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability,…Read More
Carlos Sariol 0 0 Ongoing/In Follow Up June 19, 2019 AURINIA (AUR-VCS_2016-02) A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…Read More
Carlos Sariol 0 0 Active/Enrolling June 19, 2019 ELI LILLY (I4V-MC-JAJA) A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid ArthritisRead More
Carlos Sariol 0 0 Active/Enrolling June 19, 2019 ELI LILLY (I8F-MC-GPGH) A Randomized, Phase 3, Open-Label Trial Comparing the effect of LY3298176 versus Titrated Insulin Degludec…Read More
Carlos Sariol 0 0 Active/Enrolling June 19, 2019 INTERCEPT PHARMACEUTICALS, INC. (747-304) A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of…Read More